The SURPASS-1 trial investigated the efficacy and safety of the three doses of 5, 10, or 15 mg tirzepatide in drug-nave patients with T2D who were not sufficiently controlled with a lifestyle intervention with diet and exercise versus placebo (70)
Which suite number is current has not been independently confirmed
Its impact is experienced even on a cellular level, which eventually affects ones overall health and well- being
Rather than being direct alternatives, they are often viewed as complementary research tools
For active adults, former athletes, busy parents, and patients across Princeton, Lawrenceville, West Windsor, Plainsboro, Hopewell, Pennington, Robbinsville, and Mercer County NJ, this is an important mindset shift
Proof is on the way